vialaudit
The Roundup
retatrutide · arizona

Is Retatrutide legal in Arizona?

status · caveats apply
Investigational GLP-1/GIP/glucagon triple agonist; no FDA approval; FDA has issued multiple Warning Letters to vendors marketing it for human use. No state-level peptide restrictions beyond federal law in Arizona.

category: investigational · last verified May 13, 2026

§ 01

Quick answer

Investigational GLP-1/GIP/glucagon triple agonist; no FDA approval; FDA has issued multiple Warning Letters to vendors marketing it for human use. No state-level peptide restrictions beyond federal law in Arizona.
§ 02

Full status breakdown

Federal status

FDA approval
investigational
Indications: obesity (Phase 3 TRIUMPH); T2DM; MASH; OSA; knee OA
DEA scheduling
not scheduled
503A compounding
Bulks list: not on list
Do-not-compound list: not on list
FDA stated retatrutide cannot be lawfully compounded under §503A because it is not on the bulks list and is not a component of an approved drug.
FDA Warning Letters
  • Dec 10, 2024 — Summit Research Peptides (cited: retatrutide, tirzepatide) · letter ↗
  • Dec 10, 2024 — Xcel Research LLC (cited: retatrutide, cagrilintide, mazdutide) · letter ↗
  • Sep 9, 2025 — GLP-1 Solution (cited: retatrutide) · letter ↗
  • Mar 31, 2026 — Gram Peptides (cited: retatrutide, tirzepatide) · letter ↗
  • Mar 31, 2026 — Prime Sciences (cited: retatrutide) · letter ↗
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: FDA has consistently rejected 'research use only' labeling as a safe harbor when site evidence (dosing instructions, vials/syringes, comparisons to weight-loss drugs) shows human-use intent. Multiple Warning Letters cite this exact pattern for retatrutide.
Personal possession: Personal possession of unapproved investigational peptides sits in a regulatory gray zone. FDA enforcement focus has been on vendor-side marketing and sale, not buyer-side possession, but no formal safe harbor exists.

Arizona — state-specific

Sport-body status

WADA 2026
on prohibited list · class S2 · both
Captured under S2 (Peptide hormones, growth factors, related substances and mimetics) as a glucagon/GIP/GLP-1 triple receptor agonist; also implicated under S0 (non-approved substances).
USADA
NCAA

What we couldn’t verify

§ 03

Also known as

Retatrutide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

  • LY3437943
  • GLP-3
  • triple-G
  • GGG triple agonist
  • GLP-1/GIP/glucagon triple agonist
  • RETA
  • R-10mg
§ 04

Disclaimer

§ 05

Related

the roundup · monthly

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 subscribers· 0 sponsored items· 11 issues since launch